Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Rajni Sethi, Nicholas SanfilippoDepartment of Radiation Oncology, New York University Langone Medical Center, New York, NY, USAAbstract: Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some pa...
Main Authors: | Rajni Sethi, Nicholas Sanfilippo |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-06-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/six-month-depot-formulation-of-leuprorelin-acetate-in-the-treatment-of-peer-reviewed-article-CIA |
Similar Items
-
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
by: Tunn UW, et al.
Published: (2013-04-01) -
LEUPRORELIN ACETATE DEPOT (ELIGARD) IN THE TREATMENT OF PROSTATE CANCER: WHAT DO PATIENTS WIN?
by: V. B. Matveev, et al.
Published: (2014-08-01) -
LEUPRORELIN ACETATE DEPOT (ELIGARD) IN THE TREATMENT OF PROSTATE CANCER: WHAT DO PATIENTS WIN?
by: V. B. Matveev, et al.
Published: (2014-08-01) -
A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin
by: Dohee Kim, et al.
Published: (2019-10-01) -
INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)